Survey of proper use and occurrence of hyperkalemia after administration of MINNEBRO tablets in patients with hypertension- EBM Provider Cohort Study
Not Applicable
Recruiting
- Conditions
- hypertension
- Registration Number
- JPRN-jRCT2031210422
- Lead Sponsor
- Matsuoka Yomei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15000
Inclusion Criteria
Prescription of MINNEBRO tablets has commenced during the enrollment period (May 13, 2019 to May 31, 2023).
The diagnosis of hypertension exists on the same month as the date of the first prescription of this drug during the enrollment period.
The date of the earliest medical record after the start date of the data period is 180 days or more prior to the date of the first prescription of this drug.
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Conduct serum potassium testing,, Development of hyperkalemia
- Secondary Outcome Measures
Name Time Method